Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: Quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex

Drug Metabolism and Disposition

Volumn 42, Issue 1, 2014, Pages 78-88

  Prasad, Bhagwat ^a   Evers, Raymond ^b   Gupta, Anshul ^c   Hop, Cornelis E C A ^d   Salphati, Laurent ^d   Shukla, Suneet ^e   Ambudkar, Suresh V ^e   Unadkat, Jashvant D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ASTRAZENECA   (United Kingdom)

^d GENENTECH INC   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CYTOSINE; GUANINE; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER B; POLYPEPTIDE; REPAGLINIDE; ROSUVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; TRYPSIN;

AGE; ALLELE; ARTICLE; CELL ISOLATION; CELL MEMBRANE; CONTROLLED STUDY; CRYOPRESERVATION; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; LIVER CELL; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN ISOLATION; SEX; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1B1 GENE; SLCO1B3 GENE; TANDEM MASS SPECTROMETRY; TISSUE SECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CARBAMATES; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, LIQUID; FEMALE; FLUOROBENZENES; HAPLOTYPES; HEPATOCYTES; HUMANS; INDIVIDUALITY; INFANT; LIVER; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PIPERIDINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIMIDINES; SULFONAMIDES; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84890663852     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.053819     Document Type: Article

References (44)

1. Alexandridis G, Pappas GA, and Elisaf MS (2000) Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil. Am J Med 109:261-262.
2. Backman JT, Kyrklund C, Neuvonen M, and Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685-691. (Pubitemid 36021007)
3. Bailey KM, Romaine SP, Jackson BM, Farrin AJ, Efthymiou M, Barth JH, Copeland J, McCormack T, Whitehead A, and Flather MD, et al.; SPACE ROCKET Trial Group (2010) Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circ Cardiovasc Genet 3:276-285.
4. Balogh LM, Kimoto E, Chupka J, Zhang H, and Lai Y (2012) Membrane protein quantification by peptide-based mass spectrometry approaches: studies on the organic anion-transporting polypeptide family. J Proteomics Bioinform 84:1-8.
5. Bi YA, Kimoto E, Sevidal S, Jones HM, Barton HA, Kempshall S, Whalen KM, Zhang H, Ji C, and Fenner KS, et al. (2012) In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation. Drug Metab Dispos 40:1085-1092.
6. Bosch Rovira T, Llompart Pou JA, and Forteza-Rey J (2001) [Rhabdomyolysis associated with combined treatment of cerivastatin and gemfibrozil]. Rev Clin Esp 201:731-732.
7. Chu X, Bleasby K, and Evers R (2013) Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opin Drug Metab Toxicol 9:237-252.
8. Deo AK, Prasad B, Balogh L, Lai Y, and Unadkat JD (2012) Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry. Drug Metab Dispos 40:852-855.
9. Donnelly LA, Doney AS, Tavendale R, Lang CC, Pearson ER, Colhoun HM, McCarthy MI, Hattersley AT, Morris AD, and Palmer CN (2011) Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther 89:210-216.
10. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
11. Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, Egan D, Sora ES, James CE, Gibbons S, and Bray PG, et al. (2010) HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 20:112-120.
12. Harwood MD, Neuhoff S, Carlson GL, Warhurst G, and Rostami-Hodjegan A (2013) Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. Biopharm Drug Dispos 34:2-28.
13. Ji C, Tschantz WR, Pfeifer ND, Ullah M, and Sadagopan N (2012) Development of a multiplex UPLC-MRM MS method for quantification of human membrane transport proteins OATP1B1, OATP1B3 and OATP2B1 in in vitro systems and tissues. Anal Chim Acta 717:67-76.
14. Kalliokoski A, Backman JT, Neuvonen PJ, and Niemi M (2008a) Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenet Genomics 18:937-942.
15. Kalliokoski A, Neuvonen M, Neuvonen PJ, and Niemi M (2008b) The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. Br J Clin Pharmacol 66:818-825.
16. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, and Chiba K (2005) Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15 +C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15:513-522. (Pubitemid 41017600)
17. Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, Sekine Y, Uchida Y, Ito S, and Terasaki T (2008) Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res 25:1469-1483.
18. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, and Artursson P (2012) Classification of inhibitors of hepatic organic anion transporting pol-ypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem 55: 4740-4763.
19. Kimoto E, Yoshida K, Balogh LM, Bi YA, Maeda K, El-Kattan A, Sugiyama Y, and Lai Y (2012) Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. Mol Pharm 9:3535-3542.
20. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, and Collins R; SEARCH Collaborative Group (2008) SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 359:789-799.
21. Lon HK, Liu D, and Jusko WJ (2012) Pharmacokinetic/pharmacodynamic modeling in inflammation. Crit Rev Biomed Eng 40:295-312.
22. Marsà Carretero M, Alos Manrique C, and Valles Callol JA (2002) Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen. Br J Gen Pract 52:235-236.
23. Meier Y, Pauli-Magnus C, Zanger UM, Klein K, Schaeffeler E, Nussler AK, Nussler N, Eichelbaum M, Meier PJ, and Stieger B (2006) Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 44:62-74. (Pubitemid 44049139)
24. Mwinyi J, Johne A, Bauer S, Roots I, and Gerloff T (2004) Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 75:415-421. (Pubitemid 38534562)
25. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, and Neuvonen PJ, et al. (2004) High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14:429-440. (Pubitemid 38971233)
26. Nies AT, Niemi M, Burk O, Winter S, Zanger UM, Stieger B, Schwab M, and Schaeffeler E (2013) Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med 5:1-11.
27. Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Saito A, Ishiguro N, Kishimoto W, Ludwig-Schwellinger E, and Ebner T, et al. (2012) Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos 40:83-92.
28. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562. (Pubitemid 28016533)
29. Prasad B, Lai Y, Lin Y, and Unadkat JD (2013) Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype. J Pharm Sci 102:787-793.
30. Rodrigues AC, Perin PM, Purim SG, Silbiger VN, Genvigir FD, Willrich MA, Arazi SS, Luchessi AD, Hirata MH, and Bernik MM, et al. (2011) Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A.G variant is determinant of increased atorvastatin response. Int J Mol Sci 12:5815-5827.
31. Sauna ZE, Nandigama K, and Ambudkar SV (2006) Exploiting reaction intermediates of the ATPase reaction to elucidate the mechanism of transport by P-glycoprotein (ABCB1). J Biol Chem 281:26501-26511. (Pubitemid 44401859)
32. Schaefer O, Ohtsuki S, Kawakami H, Inoue T, Liehner S, Saito A, Sakamoto A, Ishiguro N, Matsumaru T, and Terasaki T, et al. (2012) Absolute quantification and differential expression of drug transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in cultured primary human hepatocytes. Drug Metab Dispos 40:93-103.
33. Schipani A, Egan D, Dickinson L, Davies G, Boffito M, Youle M, Khoo SH, Back DJ, and Owen A (2012) Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. Antivir Ther 17:861-868.
34. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, and Raza A (2004) The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75:455-463. (Pubitemid 38534566)
35. Shitara Y, Hirano M, Sato H, and Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228-236. (Pubitemid 39287802)
36. Shitara Y, Horie T, and Sugiyama Y (2006) Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425-446. (Pubitemid 43363338)
37. Sortica VA, Fiegenbaum M, Lima LO, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, and Hutz MH (2012) SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians. Clin Chem Lab Med 50:441-448.
38. Tirona RG, Leake BF, Merino G, and Kim RB (2001) Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J Biol Chem 276:35669-35675.
39. Tomlinson B, Hu M, Lee VW, Lui SS, Chu TT, Poon EW, Ko GT, Baum L, Tam LS, and Li EK (2010) ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther 87:558-562.
40. Tucker TG, Milne AM, Fournel-Gigleux S, Fenner KS, and Coughtrie MW (2012) Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum. Biochem Pharmacol 83:279-285.
41. Varma MV, Lai Y, Feng B, Litchfield J, Goosen TC, and Bergman A (2012) Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm Res 29:2860-2873.
42. Varma MV, Lai Y, Kimoto E, Goosen TC, El-Kattan AF, and Kumar V (2013) Mechanistic modeling to predict the transporter-and enzyme-mediated drug-drug interactions of repagli-nide. Pharm Res 30:1188-1199.
43. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, and Ginsburg GS (2009) The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 54: 1609-1616.
44. Zhang Y, Li N, Brown PW, Ozer JS, and Lai Y (2011) Liquid chromatography/tandem mass spectrometry based targeted proteomics quantification of P-glycoprotein in various biological samples. Rapid Commun Mass Spectrom 25:1715-1724.